Chemotherapy-Free Salvage Therapy with Rituximab, Lenalidomide, and Poseltinib in Relapsed or Refractory Primary Central Nervous System Lymphoma: A Multi-Center, Phase II Study
Poseltinib in combination with lenalidomide and rituximab showed activity in patients with R/R PCNSL, warranting further investigation in larger studies.
Authors
- Youngil Koh
- Ka‐Won Kang (ORCID: https://orcid.org/0000-0003-1462-0502)
- Ji Hoon Kim (ORCID: https://orcid.org/0000-0003-3924-0434)
- Sanyeowool An
- Hee Kyung Ahn (ORCID: https://orcid.org/0000-0001-7786-7233)
- Dong Hyun Kim (ORCID: https://orcid.org/0009-0000-4479-690X)
- Deok‐Hwan Yang (ORCID: https://orcid.org/0000-0003-2830-9889)
- Song Han (ORCID: https://orcid.org/0000-0001-7538-5185)
- Sang Eun Yoon (ORCID: https://orcid.org/0000-0002-2472-8691)
- Seok Jin Kim
Institutions
- Seoul National University (KR)
- Korea University (KR)
- Samsung Medical Center (KR)
- Seoul National University Hospital (KR)
- Korea Pharma (South Korea) (KR)
- Chonnam National University Hwasun Hospital (KR)
- Hallym University Sacred Heart Hospital (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Cancer Research and Treatment
- Published
- 2025-11-12
- DOI
- https://doi.org/10.4143/crt.2025.977
- Primary Topic
- CNS Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Celltrion